EZH2 and cancer: A combined analysis showed that high EZH2 expression predicted poor OS in cancer (HR 1.74, 95% CI: 1.46–2.07; p<0.00001) with significant heterogeneity (I2 = 83.9%) (Table 1 and Fig 2).